Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LK-Neo ACT
- Development stage
- Preclinical
- Lead developer
- Likang Life Sciences Holdings
- Modality
- Native Immune Cells → Adoptive Cell Transfer → Cell Therapies, Vaccines & Immunotherapeutics, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Administration
- Intravenous
01
Overview
LK-Neo ACT is a neoantigen-specific adoptive T cell therapy developed by Likang Life Sciences (Beijing Likang Life Technology Co., Ltd.) for the treatment of cancer. It is classified as an antineoplastic and immunotherapy agent, specifically a T-lymphocyte cell therapy. The mechanism of action involves immunologic cytotoxicity and T lymphocyte replacement, aiming to target tumor-specific neoantigens in neoplasms. As of the latest updates, it is in preclinical development for cancer indications[1][2].
02
Targets
pMHC (Peptide-MHC complex family)
Beyond the preview
Go deeper on LK-Neo ACT.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LK-Neo ACT.